Sino-Argi Leading Biosciences
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products. It also provides plant protection technology services; and crop health solutions, including technical guidance, application demonstration, and processing and packaging of plant protection products. In addition, the company… Read more
Sino-Argi Leading Biosciences (603970) - Total Assets
Latest total assets as of September 2025: CN¥6.56 Billion CNY
Based on the latest financial reports, Sino-Argi Leading Biosciences (603970) holds total assets worth CN¥6.56 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sino-Argi Leading Biosciences - Total Assets Trend (2012–2024)
This chart illustrates how Sino-Argi Leading Biosciences’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sino-Argi Leading Biosciences - Asset Composition Analysis
Current Asset Composition (December 2024)
Sino-Argi Leading Biosciences's total assets of CN¥6.56 Billion consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.2% |
| Accounts Receivable | CN¥1.74 Billion | 31.1% |
| Inventory | CN¥1.57 Billion | 28.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥3.65 Million | 0.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Sino-Argi Leading Biosciences's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sino-Argi Leading Biosciences's current assets represent 95.6% of total assets in 2024, a decrease from 98.1% in 2012.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2024, up from 6.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 31.1% of total assets.
Sino-Argi Leading Biosciences Competitors by Total Assets
Key competitors of Sino-Argi Leading Biosciences based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥49.93 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
Sino-Argi Leading Biosciences - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sino-Argi Leading Biosciences generates 1.89x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sino-Argi Leading Biosciences generates $ 3.63 in net profit.
Sino-Argi Leading Biosciences - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 1.32 | 1.34 |
| Quick Ratio | 0.92 | 0.94 | 0.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.49 Billion | CN¥ 1.40 Billion | CN¥ 972.54 Million |
Sino-Argi Leading Biosciences - Advanced Valuation Insights
This section examines the relationship between Sino-Argi Leading Biosciences's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -6.8% |
| Total Assets | CN¥5.60 Billion |
| Market Capitalization | $192.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sino-Argi Leading Biosciences's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sino-Argi Leading Biosciences's assets decreased by 6.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sino-Argi Leading Biosciences (2012–2024)
The table below shows the annual total assets of Sino-Argi Leading Biosciences from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.60 Billion | -6.76% |
| 2023-12-31 | CN¥6.01 Billion | -3.78% |
| 2022-12-31 | CN¥6.24 Billion | +31.68% |
| 2021-12-31 | CN¥4.74 Billion | +17.84% |
| 2020-12-31 | CN¥4.02 Billion | +46.89% |
| 2019-12-31 | CN¥2.74 Billion | +5.98% |
| 2018-12-31 | CN¥2.58 Billion | -7.12% |
| 2017-12-31 | CN¥2.78 Billion | +7.80% |
| 2016-12-31 | CN¥2.58 Billion | +2.60% |
| 2015-12-31 | CN¥2.52 Billion | +28.42% |
| 2014-12-31 | CN¥1.96 Billion | +18.43% |
| 2013-12-31 | CN¥1.65 Billion | +34.16% |
| 2012-12-31 | CN¥1.23 Billion | -- |